CTLA4 and hepatocellular carcinoma: Though monotherapy with axitinib showed no significant survival benefits, the combination of anti-PD-1/PD-L1, anti-CTLA-4, or other tyrosine kinase inhibitors (TKIs) may be a promising regimen for advanced HCC.